Publications by authors named "Paul Harrow"
Background: Ustekinumab was approved in 2016 for the treatment of moderate-severe Crohn's disease (CD). Clinical trials and real-world studies have suggested ustekinumab to be a safe and effective treatment; however, studies to date infrequently use imaging techniques to predict response to biologics in CD.
Objectives: We assessed the 2-year real-world effectiveness and safety of ustekinumab in a tertiary CD cohort with the use of novel imaging techniques.
Article Synopsis
- The study examines the effectiveness of sequential drug treatments for ulcerative colitis (UC), specifically comparing the use of vedolizumab (VDZ) and anti-TNF therapies as second-line treatments.
- Researchers analyzed data from patients who switched treatments between May 2013 and August 2020, looking at various health outcomes over a 52-week period.
- Results indicated that patients receiving VDZ after anti-TNF had significantly better treatment persistence, colectomy-free survival, and clinical remission compared to those receiving anti-TNF after VDZ, suggesting a favorable effect of the treatment order on patient outcomes.